3D-printed ulcerative colitis treatment receives FDA clearance to start clinical trials

Nanjing, China-based Triastek, a pharmaceutical company, has received FDA investigational new drug clearance to begin clinical studies on its 3D-printed medicine, T21, designed to treat ulcerative colitis. 

Read the full post at Becker's ASC
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive